Potent Neuroprotective Activity of Monoterpene Derived 4-[(3aR,7aS)- 1,3,3a,4,5,7a-Hexahydro-3,3,6-trimethylisobenzofuran-1-yl]-2-methoxyphenol in MPTP Mice Model

Павлова, А. В.; Ильина, И. В.; Морозова, Е. А.; Корчагина, Д. В.; Kurbakova, S. Yu.; Сорокина, И. В.; Толстикова, Т. Г.; Волчо, К. П.; Salakhutdinov, N. F.

doi:10.2174/1570180811666131210000316

Cited by 11 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the studies that performed a temporal analysis, some degree of catalepsy could be observed after 30 min of administration (Barroca et al., 2019; Beurrier et al., 2009; Colombo et al., 2013; Parambi et al., 2020). A consistent catalepsy induction often appears from 60 min (Darbaky et al., 2003; Jena et al., 2014; Nuutila et al., 1987; Sharma et al., 2020) and could last up to 240–300 min after administration (Ardashov et al., 2011; Invernizzi et al., 2002; Ionov & Severtsev, 2012b; Moo‐Puc et al., 2003; Pavlova & Il’ina et al., 2014; Verhagen‐Kamerbeek et al., 1993).…”

Section: Resultsmentioning

confidence: 99%

“…(Trevitt et al., 2009; Maj et al., 1990; Juszkiewicz et al., 1994; Juszkiewicz et al., 1995; Mandhane et al., 1997; Konieczny et al., 1999; Jagtap & Inamdar, 2001; Ossowska et al., 2001; Breysse et al., 2002; Moo‐Puc et al., 2003; Ossowska et al., 2003; Rukoyatkina et al., 2003; Wardas et al., 2003; Tanganelli et al., 2004; Ossowska et al., 2005; Zazpe et al., 2006; Lopez et al., 2007; Sibille et al., 2007; Ahemad et al., 2009; Beurrier et al., 2009; Góngora‐Alfaro et al., 2009; Konieczny et al., 2009; Ardashov et al., 2011; Joshi et al., 2011; Trevizol et al., 2011; Lopez et al., 2012; Shyamjith et al., 2012; Goudet et al., 2012; Acuña‐Lizama et al., 2013; Konieczny & Lenda, 2013; Atack et al., 2014; Ittiyavira & Ruby, 2014; Azam, et al., 2009; Zheng et al., 2014; Gmiro et al., 2015; Maurice et al., 2015; Nade et al., 2015; Bhangale & Acharya, 2016; Dhingra & Gahalain, 2016; Basu et al., 2017; Chitra et al., 2017; Gupta et al., 2017; Kumari et al., 2017; Kronbauer et al., 2017; Tian et al., 2017; Yang et al., 2016; Engelhardt et al., 2018; Slee et al., 2008; Saleem et al., 2019; Kabra et al., 2020; Łażewska et al., 2020; Chiu et al., 1981; Schmidt & Bubser, 1989; Schmidt et al., 1991; Kretschmer, 1994; Kretschmer et al.,…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Waku

Magalhães

Alves

et al. 2021

Eur J of Neuroscience

View full text Add to dashboard Cite

Several useful animal models for parkinsonism have been developed so far. Haloperidol‐induced catalepsy is often used as a rodent model for the study of motor impairments observed in Parkinson's disease and related disorders and for the screening of potential antiparkinsonian compounds. The objective of this systematic review is to identify publications that used the haloperidol‐induced catalepsy model for parkinsonism and to explore the methodological characteristics and the main questions addressed in these studies. A careful systematic search of the literature was carried out by accessing articles in three different databases: Web of Science, PubMed and SCOPUS. The selection and inclusion of studies were performed based on the abstract and, subsequently, on full‐text analysis. Data extraction included the objective of the study, study design and outcome of interest. Two hundred and fifty‐five articles were included in the review. Publication years ranged from 1981 to 2020. Most studies used the model to explore the effects of potential treatments for parkinsonism. Although the methodological characteristics used are quite varied, most studies used Wistar rats as experimental subjects. The most frequent dose of haloperidol used was 1.0 mg/kg, and the horizontal bar test was the most used to assess catalepsy. The data presented here provide a framework for an evidence‐based approach to the design of preclinical research on parkinsonism using the haloperidol‐induced catalepsy model. This model has been used routinely and successfully and is likely to continue to play a critical role in the ongoing search for the next generation of therapeutic interventions for parkinsonism.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Waku

Magalhães

Alves

et al. 2021

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

“…Previously, we showed that condensation of 2-carene 9 with aldehydes 10a–c in the presence of montmorillonite clays led to the formation of hexahydroisobenzofurans 11a–c as a mixture of two isomers at the C(1) position and compounds with 3-oxabicyclo[3.3.1]nonane structure 12 as minor products ( Scheme 1 ). It was found that hexahydroisobenzofuran 11a obtained with condensation of 2-carene 9 with 4-hydroxy-3-methoxybenzaldehyde 10a demonstrated potent neuroprotective activity in an in vivo Parkinson model combined with low acute toxicity [ 24 ]. The reactions of 3-carene 8 with aldehydes gave the same products 11 and 12 as it did for 2-carene 9 but in much lower yields (only 3% for the reaction with aldehyde 10a ), since 2-carene 9 is more reactive due to the conjugation of the double bond with the cyclopropane ring [ 23 ].…”

Section: Resultsmentioning

confidence: 99%

“…It has been shown that carene can be successfully reacted with carbonyl compounds [23,24]. Previously, we showed that condensation of 2-carene 9 with aldehydes 10a-c in the presence of montmorillonite clays led to the formation of hexahydroisobenzofurans 11a-c as a mixture of two isomers at the C(1) position and compounds with 3-oxabicyclo[3 .3.1]nonane structure 12 as minor products (Scheme 1).…”

Section: Chemistrymentioning

confidence: 99%

Design, Synthesis, and Biological Investigation of Novel Classes of 3-Carene-Derived Potent Inhibitors of TDP1

et al. 2020

View full text Add to dashboard Cite

Two novel structural types of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors with hexahydroisobenzofuran 11 and 3-oxabicyclo [3.3.1]nonane 12 scaffolds were discovered. These monoterpene-derived compounds were synthesized through preliminary isomerization of (+)-3-carene to (+)-2-carene followed by reaction with heteroaromatic aldehydes. All the compounds inhibit the TDP1 enzyme at micro- and submicromolar levels, with the most potent compound having an IC50 value of 0.65 μM. TDP1 is an important DNA repair enzyme and a promising target for the development of new chemosensitizing agents. A panel of isogenic clones of the HEK293FT cell line knockout for the TDP1 gene was created using the CRISPR-Cas9 system. Cytotoxic effects of topotecan (Tpc) and non-cytotoxic compounds of the new structures were investigated separately and jointly in the TDP1 gene knockout cells. For two TDP1 inhibitors, 11h and 12k, a synergistic effect was observed with Tpc in the HEK293FT cells but was not found in TDP1 −/− cells. Thus, it is likely that the synergistic effect is caused by inhibition of TDP1. Synergy was also found for 11h in other cancer cell lines. Thus, sensitizing cancer cells using a non-cytotoxic drug can enhance the efficacy of currently used pharmaceuticals and, concomitantly, reduce toxic side effects.

show abstract

“…Известно, что многие производные изобензофурана (ИБФ) обладают противораковым, тромболитическим, антидепрессантным и другим действием [2][3][4][5]. Так, ИБФ, полученные при взаимодействии 1 с ванилином, обладают высокой нейропро-текторной активностью на модели болезни Паркинсона in vivo [6]. Ввиду того, что 2-карен 1 является труднодоступным соединением, ранее нами был разработан метод каталитического синтеза изобензофуранов из 3-карена через его изомеризацию в 1 на кислотных глинах без предварительного разделения реакционной смеси [7].…”

unclassified

Preparation of chiral izobenzofuranes based on 3-carene in the presence of halloysite nanocatalysts

Sidorenko¹,

Агабеков²,

Волчо³

et al. 2020

Dokl. Akad. nauk

View full text Add to dashboard Cite

ПОЛУЧЕНИЕ ХИРАЛЬНЫХ ИЗОБЕНЗОФУРАНОВ НА ОСНОВЕ 3-КАРЕНА В ПРИСУТСТВИИ ГАЛЛУАЗИТОВЫХ НАНОКАТАЛИЗАТОРОВ Аннотация. Исследовано взаимодействие содержащих 2-карен продуктов изомеризации 3-карена с 4-метоксибензальдегидом в присутствии обработанных 5,0 % HCl галлуазитовых нанотрубок. Основными продуктами реакции являются хиральные производные изобензофурана. Селективность по этим соединениям (71,4 %) сопоставима с таковой при использовании труднодоступного индивидуального 2-карена. Показана возможность использования галлуазитовых нанокатализаторов для селективного получения изобензофурановых соединений на основе продуктов изомеризации 3-карена (компонента живичного скипидара) без предварительного разделения смеси. Ключевые слова: 3-карен, галлуазитовые нанотрубки, 2-карен, изобензофураны Для цитирования: Получение хиральных изобензофуранов на основе 3-карена в присутствии галлуазитовых нанокатализаторов / А. Ю. Сидоренко [и др.]

show abstract

Potent Neuroprotective Activity of Monoterpene Derived 4-[(3aR,7aS)- 1,3,3a,4,5,7a-Hexahydro-3,3,6-trimethylisobenzofuran-1-yl]-2-methoxyphenol in MPTP Mice Model

Cited by 11 publications

References 0 publications

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Design, Synthesis, and Biological Investigation of Novel Classes of 3-Carene-Derived Potent Inhibitors of TDP1

Preparation of chiral izobenzofuranes based on 3-carene in the presence of halloysite nanocatalysts

Contact Info

Product

Resources

About